Ablative Therapy in the Management of Prostate Cancer

Part of paid clinical trials in New York, New York.

Sponsor
Weill Medical College of Cornell University
Study ID
NCT03492424
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • cryotherapy — DEVICE
    Subjects will receive focal cryotherapy for treatment of prostate cancer

Study Details

The purpose of this study is collect observational data regarding patterns of care and outcomes of focal therapies for prostate cancer, including but not limited to: high-intensity focused ultrasound (HIFU), cryotherapy, focal laser ablation, irreversible electroporation, photodynamic therapy, and brachytherapy.

Key Dates

Start date
Jan 2, 2018
Status verified
Dec 2025
Primary completion
Mar 2, 2032
Completion
Sep 2, 2039

Study Design

Enrollment
200 participants (estimated)

Arms

  • Arm: Focal therapy for prostate cancer
    All men \>18 years of age undergoing focal therapy for primary or salvage treatment of prostate cancer will be included. Men who had received prior focal therapy are also eligible for inclusion. The purpose of this study is collect observational data regarding patterns of care and outcomes of focal therapies for prostate cancer, including but not limited to: high-intensity focused ultrasound (HIFU), cryotherapy, focal laser ablation, irreversible electroporation, photodynamic therapy, and brachytherapy.

Primary Outcome Measure

Prostate biopsy Gleason grade [ Time Frame: 12 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Weill Cornell MedicineNew YorkNew York10065
Holly Kuczynski
[email protected]
646-962-7523
Tim McClure, M.D. (PRINCIPAL_INVESTIGATOR)

Find similar trials in New York, NY

By condition
Prostate cancer
By specialty
OncologyProstate oncologyMen's healthUrology
By research site
Weill Cornell Medicine· New York, NY

Related Studies